Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

To date, almost 400 reports of acute pancreatitis have been received from people using GLP-1 drugs such as Mounjaro, Wegovy, ...

Weight-loss drugs like Ozempic, while revolutionary, are under scrutiny as the UK's MHRA investigates serious pancreas trouble reported by GLP-1 users ...

Delhi High Court asks drug regulator to look into concerns over approval for weight-loss drugs A PIL has claimed that licences for these drugs were issued without adequate data or India-specific ...

CVS is set to drop Zepbound as a medicine, but will continue to carry other popular weight loss drugs instead.

Novo Nordisk has submitted a new, higher dose of its obesity treatment, Wegovy, for approval to the European Medicines Agency ...

The evolution of controversial new weight loss drugs is shining a spotlight on a crippling, little-understood food phenomenon ...

Kids younger than 6 years on extended-release stimulants for ADHD may experience higher rates of side effects due to higher plasma exposures.

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...

Delhi High Court on Wednesday asked Drug Controller General of India (DCGI) to consult experts and relevant stakeholders ...